[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100129161":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":20,"studyPopulation":21,"armGroups":22,"interventions":28,"overallOfficials":33,"centralContacts":38,"locations":47,"responsibleParty":64,"collaborators":11,"id":66,"slug":11,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":11,"studyType":79,"phases":11,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":50,"whyStopped":11,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Jonsson Comprehensive Cancer Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Discover and confirm clinical parameters that predict aggressive disease as defined by pre-specified histological, PSA, clinical criteria, or outcomes based on these variables.",null,"Interim data analysis will be made every year",[14],{"measure":15,"description":11,"timeFrame":16},"Determine the clinical predictors of disease progression. Measure the recurrence-free, disease-specific, and overall survival of men on active surveillance for clinically localized prostate cancer. Determine factors that lead to active intervention","Interim data analysis will be done each year",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":18,"timePerspective":19,"maskingInfo":11},"ECOLOGIC_OR_COMMUNITY","PROSPECTIVE","This protocol is not designed as a formal clinical trial, but rather an observational protocol; no treatments and no randomization are included. Longitudinally, specimens and clinical data will be collected to provide information on the following:\n\n* Imaging studies of the prostate\n* Rates of curative intervention\n* Measures of tumor recurrence\u002Fprogression\n* Disease specific survival\n* Overall survival\n* Clinical data to track Quality of Life","Community sample",[23],{"label":24,"type":11,"description":25,"interventionNames":26},"no treatment","Men with previously untreated, early stage prostate cancer.",[27],"Other: Active surveillance",[29],{"type":6,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"Active surveillance","Serial, long term data collection and active surveillance",[24],[34],{"name":35,"affiliation":36,"role":37},"Leonard S Marks, M.D.","University of California, Los Angeles","PRINCIPAL_INVESTIGATOR",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":11,"email":43},"Malu Macairan","CONTACT","(310) 794-3566","mmacairan@mednet.ucla.edu",{"name":35,"role":41,"phone":45,"phoneExt":11,"email":46},"(310) 794-3070","lmarks@mednet.ucla.edu",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"University of California Los Angeles","RECRUITING","Los Angeles","California","90095","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-118.24368,34.05223,{"lat":60,"lon":59},[63],{"name":35,"role":37,"phone":11,"phoneExt":11,"email":11},{"type":65,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100129161",false,"NCT00949819","Active Surveillance for Cancer of the Prostate (ASCaP)","The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.","ASCaP","Inclusion Criteria:\n\n1. Histologically confirmed adenocarcinoma of the prostate.\n2. Clinically localized prostate cancer: T1-2, NX or N0, MX or M0.\n3. No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy).\n4. Patient has elected Active Surveillance as preferred management plan for prostate cancer.\n5. Patient consent has been obtained according to local Institutional Review Board .\n6. Patient is accessible and compliant for follow-up.\n\nExclusion Criteria:\n\n1. Unwillingness or inability to undergo serial prostate biopsy.\n2. Overall life expectancy less than 2 years\n3. Advanced prostate cancer","MALE","30 Years","85 Years",{"count":77,"type":78},462,"ESTIMATED","OBSERVATIONAL","Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with low-risk, localized lesions, with curative treatment of those whose tumors show substantial progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative treatment of men with progressive prostate cancer.",[82],"Prostate Cancer",[82,84,85,30],"Low risk","Gleason 6","2026-05-21",{"date":88,"type":89},"2026-05-26","ACTUAL",{"date":91,"type":89},"2009-07-04",{"date":93,"type":78},"2028-12",{"name":5,"class":6},1]